Quintrio
Home

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Intuitive Surgical Inc.

ISRG

Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 11,000 da Vinci systems in hospitals worldwide, with more than 6,600 installations in the US and a growing number in emerging markets.

Last trade $432.52
Day change -$5.235 (-1.20%)
Day range $428.78 – $441.28
Volume 1,514,061
Market cap $151.74B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$151.74B
Price / earnings
51.31×
Price / book
9.49×
Price / sales
13.11×
EV / sales
12.85×
EV / EBITDA
33.36×

Profitability

Earnings per share
$8.53
Return on assets
15.28%
Return on equity
18.5%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.33×
Quick ratio
2.49×
Cash ratio
1.18×

Cash flow

Price / cash flow
37.11×
Price / free cash flow
42.17×
Free cash flow
$3.6B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ISRG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.05B$2.89B$2.77B$2.87B$2.51B$2.44B$2.25B$2.41B
Cost of revenue$964.4M$931.9M$940.3M$961.9M$842.7M$822.1M$795.7M$771.3M
Gross profit$2.08B$1.96B$1.83B$1.9B$1.66B$1.62B$1.46B$1.64B
Selling, general and administrative$633.4M$617.9M$613.3M$687.1M$573.3M$561.2M$563.4M$612.6M
Research and development$408.3M$370.6M$361.9M$352.9M$329.4M$313.3M$316.2M$294.7M
Total operating expenses$1.49B$988.5M$975.2M$1.04B$902.7M$874.5M$879.6M$907.3M
Operating income$592.6M$971.9M$855.3M$864.3M$759.7M$743.4M$578.1M$734.9M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$668.4M$1.05B$940.4M$955.6M$855.2M$832.1M$668.5M$809.8M
Income taxes$144M$231.4M$114.4M$156.1M$146M$167.9M-$35.2M$121.8M
Net income$524.4M$823.2M$826M$799.5M$709.2M$664.2M$703.7M$688M
Net income attributable to common shareholders$522.8M$818.1M$821.5M$794.8M$704.4M$658.4M$698.4M$685.7M
EBITDA$1.07B$1.01B$876.4M$1.5B$772.6M$755.7M$590.2M$1.19B
Basic earnings per share$1.50$2.31$2.31$2.24$1.98$1.84$1.95$1.92
Diluted earnings per share$1.49$2.29$2.28$2.21$1.95$1.81$1.92$1.88

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know

Intuitive Surgical (ISRG) has been heavily searched by investors and shows strong fundamentals with a Zacks Rank #2 (Buy) rating. The company is expected to post 17% year-over-year earnings growth for the current quarter and 25.9% for the fiscal year, with consensus estimates revised upward by 5.6% over the past month. However, the stock is trading at a premium valuation (F grade) compared to peers, and revenue growth forecasts show 18.4% and 11.6% increases for current and next fiscal years respectively.

Zacks Investment Research

Here's Why You Should Add GEHC Stock to Your Portfolio Right Now

GE HealthCare Technologies (GEHC) is well-positioned for growth with a record $23.7 billion backlog (up 12%), strong Pharmaceutical Diagnostics revenue growth, and raised 2026 guidance. However, persistent component inflation, tariff uncertainty, and China's fragile recovery pose risks to margin expansion.

Zacks Investment Research

ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?

Intuitive Surgical delivered robust Q3 2026 results with adjusted EPS up 25% to $3 and revenue growth of 22% to $3.1 billion, driven by expanding robotic platform adoption and improved operating efficiency. The company maintains a 42% operating margin while investing heavily in R&D for AI features and new platforms. However, reported GAAP net income declined due to a $450 million litigation settlement. Peer medical device makers Stryker and Medtronic also posted strong earnings growth, though facing headwinds from procedure volume pressures and supply constraints.

Zacks Investment Research

DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems

Doximity announced an expansion of its AI-powered clinical tools partnership with NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine. The collaboration includes Doximity Ask (clinical decision support integrated with Epic EHR) and Doximity Scribe (patient documentation and dictation). The company also launched DoseCheck, a safety feature reducing dosing errors by over 99%. Despite the positive developments, DOCS stock has declined 24.7% year-to-date.

Zacks Investment Research

Here's Why You Should Retain PHG Stock in Your Portfolio for Now

Koninklijke Philips reported strong equipment order intake growth of 8% with Diagnosis & Treatment orders surging nearly 20%, and Personal Health sales rising 8%. However, ultrasound manufacturing delays, China's pricing pressure from centralized procurement, and inflation concerns pose significant risks to profitability and growth trajectory. The company maintains a Zacks Rank #3 (Hold) rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 5, 20213-for-1forward split
Oct 6, 20173-for-1forward split
Jul 1, 20031-for-2reverse split